Lifordi Immunotherapeutics just locked down a fresh $42M in Series A-II funding, pushing total capital to $112M and sending a clear signal that the autoimmune world is about to get a little less chaotic. Sanofi Ventures stepped in to lead the round, with ARCH Venture Partners, 5AM Ventures, and Atlas Venture returning like the seasoned judges who already know the track is a hit before the crowd even reacts. Add in Christopher Gagliardi joining as a board observer and the whole raise moves with the authority of people who have seen great science turn into real medicine more than a few times.
What Lifordi is building feels like someone finally taught immunology how to stop shouting. CEO Arthur Tzianabos is steering a company that took ADC tech, usually reserved for oncology brawls, and retooled it with the finesse of a jazz trio to target immune cells with LFD-200. Their VISTA-based delivery is shaping up to be the closest thing the field has seen to an internal GPS signal guiding glucocorticoids exactly where they need to be. Phase 1 dosing is underway, early data is coming soon, and the calm confidence around the program feels earned.
CTO Dave Nichols is already scaling CMC so Phase 2 never stalls for supply, which is a luxury most early-stage biotechs only dream about. Pair that with Matthew McClure guiding clinical strategy and Jay Rothstein sharpening the biology behind VISTA targeting, and suddenly Lifordi starts looking like a team that knows the value of being early but prepared. Preclinical work showing sustained immune cell GC levels for 7 days with no cortisol issues is exactly the kind of signal the autoimmune space has been waiting on for decades.
The elegance here is in the business model hiding inside the science. Investors do not chase complexity, they chase clarity, and Lifordi serves it clean. Autoimmune patients have spent years choosing between relief and collateral damage, and LFD-200 aims to break that tradeoff. When a single subcutaneous dose can calm inflammation without setting off systemic fireworks, you unlock something bigger than a program. You unlock a platform.
With the new raise, Lifordi is expanding its VISTA-targeting engine beyond small molecules into ASOs and siRNA, setting the stage for a pipeline that could stretch across multiple immune-driven diseases. From Burlington to Lebanon and into multi-site trials, the company is moving like a group that understands momentum and respects the weight of opportunity.
Startups Startup Funding Venture Capital Series A Biotech Health Tech Healthcare Data Data Driven Technology Innovation Tech Ecosystem Startup Ecosystem Hiring Tech Hiring
